Enric Ivarez Martnez

List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/4875728/enric-alvarez-martinez-publications-by-citations.pdf$

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43 papers 1,862 25 43 g-index

43 ext. papers 2,047 ext. citations 5.6 avg, IF L-index

#	Paper	IF	Citations
43	Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. <i>Lancet, The</i> , 1997 , 349, 1594-7	40	269
42	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 589-600	5.8	152
41	Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. <i>Journal of Psychiatric Research</i> , 2011 , 45, 427-34	5.2	99
40	Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. <i>Psychological Medicine</i> , 2014 , 44, 1171-82	6.9	86
39	Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. <i>Schizophrenia Research</i> , 2015 , 161, 261-8	3.6	76
38	Decreased plasma serotonin in melancholic patients: a study with clomipramine. <i>Biological Psychiatry</i> , 1987 , 22, 1429-38	7.9	73
37	A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. <i>Journal of Affective Disorders</i> , 2010 , 120, 221-5	6.6	70
36	Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. <i>Schizophrenia Research</i> , 2009 , 115, 58-66	3.6	62
35	Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. <i>Journal of Affective Disorders</i> , 1992 , 25, 243-9	6.6	62
34	SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. <i>Psychiatry Research - Neuroimaging</i> , 2001 , 106, 151-60	2.9	56
33	Augmentation of fluoxetine\(\mathbf{w}\)antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. \(Journal of Clinical Psychopharmacology\), \(2001\), 21, 36-45	1.7	50
32	Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. <i>European Psychiatry</i> , 2006 , 21, 11-20	6	48
31	Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. <i>Psychiatric Genetics</i> , 2006 , 16, 25-9	2.9	47
30	Remission in schizophrenia: results from a 1-year follow-up observational study. <i>Schizophrenia Research</i> , 2009 , 108, 214-22	3.6	44
29	Enhanced binding of [3H] (-) adrenaline to platelets of depressed patients with melancholia: effect of long-term clomipramine treatment. <i>Acta Psychiatrica Scandinavica</i> , 1987 , 75, 150-7	6.5	44
28	Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. <i>Neuropsychopharmacology</i> , 2004 , 29, 580-8	8.7	42
27	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. <i>Psychopharmacology</i> , 2006 , 189, 145-53	4.7	40

(2012-2005)

26	Is grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analyses of schizophrenia. <i>European Psychiatry</i> , 2005 , 20, 550-3	6	40
25	Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. <i>Psychopharmacology</i> , 1989 , 99, 328-32	4.7	39
24	Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2007 , 89, 190-4	4.9	36
23	Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. <i>NeuroImage</i> , 2006 , 29, 662-6	7.9	36
22	Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment. <i>British Journal of Pharmacology</i> , 2012 , 167, 1021-34	8.6	34
21	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. <i>Psychiatry Research</i> , 2012 , 200, 693-701	9.9	26
20	Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations. <i>Schizophrenia Research</i> , 2017 , 189, 97-103	3.6	25
19	Predicting outcome of lithium added to antidepressants in resistant depression. <i>Journal of Affective Disorders</i> , 1997 , 42, 179-86	6.6	25
18	Injectable atypical antipsychotics for agitation in borderline personality disorder. <i>Pharmacopsychiatry</i> , 2006 , 39, 117-8	2	25
17	Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls. <i>Journal of Affective Disorders</i> , 1993 , 29, 227-34	6.6	25
16	Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. <i>European Neuropsychopharmacology</i> , 2010 , 20, 721-30	1.2	23
15	Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 222-30	1.7	22
14	Pindolol augmentation enhances response outcomes in first depressive episodes. <i>European Neuropsychopharmacology</i> , 2009 , 19, 516-9	1.2	21
13	Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. <i>Psychiatry Research - Neuroimaging</i> , 2006 , 148, 175-83	2.9	18
12	Immediate cerebral metabolic changes induced by discontinuation of deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2015 , 173, 159-62	6.6	17
11	Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005 , 29, 91-6	5.5	17
10	Urinary phenylacetic acid excretion in depressive patients. Acta Psychiatrica Scandinavica, 1988, 78, 208-	· 160 5	17
9	Regional differences in treatment response and three year course of schizophrenia across the world. <i>Journal of Psychiatric Research</i> , 2012 , 46, 856-64	5.2	16

8	Cognitive functioning after deep brain stimulation in subcallosal cingulate gyrus for treatment-resistant depression: an exploratory study. <i>Psychiatry Research</i> , 2015 , 225, 341-6	9.9	16	
7	Depressive relapse after initial response to subcallosal cingulate gyrus-deep brain stimulation in a patient with a treatment-resistant depression: electroconvulsive therapy as a feasible strategy. <i>Biological Psychiatry</i> , 2009 , 66, e11-2	7.9	15	
6	The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): a psychometric analysis in a clinical sample. <i>Journal of Affective Disorders</i> , 2014 , 169, 189-96	6.6	10	
5	Clinical and serotonergic predictors of non-affective acute remitting psychosis in patients with a first-episode psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 71-7	6.5	10	
4	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 767-70	5.5	10	
3	Which nontraditional outcomes should be measured in healthcare decision-making in schizophrenia? A systematic review. <i>Perspectives in Psychiatric Care</i> , 2012 , 48, 198-207	2.2	7	
2	A psychometric analysis of the Clinically Useful Depression Outcome Scale (CUDOS) in Spanish patients. <i>Journal of Affective Disorders</i> , 2013 , 151, 920-3	6.6	6	
1	Letter to the Editor: Deep brain stimulation for schizophrenia. <i>Journal of Neurosurgery</i> , 2016 , 125, 229-3	9 .2	6	